References
- Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34 https://doi.org/10.1093/jnci/91.19.1616
- Scagliotti GV, Novello S. Role of erythropoietin in the treatment of lung cancer associated anaemia. Lung Cancer 2001;34 Suppl 4:S91-4 https://doi.org/10.1016/S0169-5002(01)00355-5
- Lyman GH, Berndt ER, Kallich JD, Erder MH, Crown WH, Long SR, et al. The economic burden of anemia in cancer patients receiving chemotherapy. Value Health 2005;8:149-56 https://doi.org/10.1111/j.1524-4733.2005.03089.x
- Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP. Transfusion medicine. Second of two parts--blood conservation. N Engl J Med 1999;340:525-33 https://doi.org/10.1056/NEJM199902183400706
- Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of onceweekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82 https://doi.org/10.1200/JCO.2001.19.11.2875
- Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25 https://doi.org/10.1200/JCO.1998.16.10.3412
- Cella D, Zagari MJ, Vandoros C, Gagnon DD, Hurtz HJ, Nortier JW. Epoetin alfa treatment results in clinically significant improvements in quality of life in anemic cancer patients when referenced to the general population. J Clin Oncol 2003;21:366-73 https://doi.org/10.1200/JCO.2003.02.136
- Cella D, Kallich J, McDermott A, Xu X. The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials. Ann Oncol 2004;15:979-86 https://doi.org/10.1093/annonc/mdh235
- Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics 2005; 23:505-14 https://doi.org/10.2165/00019053-200523050-00009
- Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy- induced anemia treated in clinical practice. Oncologist 2004;9:451-8 https://doi.org/10.1634/theoncologist.9-4-451
- Waltzman R, Croot C, Justice GR, Fesen MR, Charu V, Williams D. Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy. Oncologist 2005;10:642-50 https://doi.org/10.1634/theoncologist.10-8-642
- Information for Healthcare Professionals [Internet]. Silver Spring: U.S. Food and Drug Administration/ Center for Drug Evaluation and Research; c2007. Erythropoiesis Stimulating Agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoe tin alfa)]; 2007 Feb 16 [cited 2007 Mar 21]. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/ RHE2007HCP.htm
- Senecal FM, Yee L, Gabrail N, Charu V, Tomita D, Rossi G, et al. Treatment of chemotherapy-induced anemia in breast cancer: results of a randomized controlled trial of darbepoetin alfa 200 microg every 2 weeks versus epoetin alfa 40,000 U weekly. Clin Breast Cancer 2005; 6:446-54 https://doi.org/10.3816/CBC.2005.n.050
- Aranesp (darbepoetin alfa) [package insert]. Thousand oaks, CA: Amgen Inc.; March 2008
- Procrit (epoetin alfa) [package insert]. Raritan, NJ: OrthoBiotech. L.P.; March 2008
- Lastiri JM, Specterman SR, Rendo P, Pallotta MG, Varela MS, Goldstein S. Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer. Medicina (B Aires) 2002;62:41-7
- Rodgers GM. Clinical practice guidelines in oncology: cancer and treatment-related anemia [Internet]. Fort Washington: National Comprehensive Cancer Network; 2005 [cited 2005 Dec 10]. Available from: http://www. nccn.org/professionals/physician_gls/f_guidelines.asp